PMC:7499584 / 14330-14948 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7499584","sourcedb":"PMC","sourceid":"7499584","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7499584","text":"Summary\nGlycobiologists with access to any of the compounds mentioned herein or related to glycosylation interdictors are encouraged to send their samples for testing to virology labs conducting SARS COV2/ACE2-binding studies, spike glycoprotein fusion tests, or infectivity assays. Repurposing of already approved drugs, and testing others with low toxicity may uncover other avenues from a solid glycobiology antiviral background for a much-needed development of COVID19 therapeutics. There are also outstanding opportunities for selectin anti-inflammatory and heparinoid anticoagulation approaches for COVID19 ARDS.","divisions":[{"label":"title","span":{"begin":0,"end":7}}],"tracks":[]}